Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies

 Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies

Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies

Shots:

  • Sitryx to receive $50M upfront, $10M equity investment, ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop and commercialize immunometabolism targeted therapies, including Sitryx’s two lead projects
  • The companies will collaborate for 5yrs. supporting the development of therapies with Sitryx to be responsible for drug discovery while Lilly to fund and manage the clinical & commercial activities
  • The collaboration will evaluate up to four novel preclinical targets identified by Sitryx, leading to potential therapies for autoimmune diseases

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Luckystep

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post